Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
AssigneesCentre Leon Berard, Universite Claude Bernard Lyon 1, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsStéphane DEPIL, Laurie TONON, Christophe CAUX, Paola BONAVENTURA, Jenny VALLADEAU
Life of this patent
Estimating the term…
Abstract
A composition or vaccine comprising at least one peptide, or an expression vector that induces expression of said at least one peptide in vivo, the peptide consisting of, or comprising, shared HERV-K derived antigens, and a pharmaceutically acceptable vehicle or excipient. Composition comprising Cytotoxic T Lymphocytes (CTLs) of a patient treated with such a peptide, or comprising T-cell Receptor (TCR) engineered T cells recognizing such a peptide.
Claims13
A composition comprising
- 2, 3, 4, 5, 6 or 7 peptides, or one or more expression vector(s) that induce(s) expression of said 2, 3, 4, 5, 6 or 7 peptides in vivo, the peptides having from 9 to 100 amino acid residues, each one comprising at least one of the epitopes of sequences SEQ ID NO:
- 1-7, and each peptide comprising at least one different epitope with respect to the others;
- or
- at least one peptide, or an expression vector that induces expression of said at least one peptide in vivo, said peptide having from 9 to 100 amino acids residues and comprising 2, 3, 4, 5, 6 or 7 of the epitopes of sequences SEQ ID NO:
- 1-7;
- and a pharmaceutically acceptable vehicle or excipient.
Isolated peptide selected from the group consisting of the peptides of sequence SEQ ID NO:
- 2-14, and the peptides having 10 to 100, 70, 50, 40, 30, 25, or 20 amino acids and comprising at least one of said peptides of SEQ ID NO:
- 2-7.
Dependencies are inferred from the claim text.